`

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Pacific Software, Inc.

732 S 6th Ste R
Las Vegas, Nevada 89101
www.purminds.com
info@purminds.com
SIC: 8731

Quarterly Report
For the Period Ending: March 31, 2026
(the "Reporting Period")

Outstanding Shares
The number of shares outstanding of our Common Stock was:

- 773,446,598 as of March 31, 2026
- 643,500,732 as of December 31, 2025
- 47,281,336 as of September 30, 2025
- 40,032,889 as of June 30, 2025
- 40,032,889 as of March 31, 2025
- 40,032,889 as of December 31, 2024
- 40,536,222 as of September 30, 2024

Shell Status
Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control
Indicate by check mark whether a Change in Control[1] of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Incorporated as Pacific Mining, Inc., on October 12, 2005; changed to Pacific Software, Inc. as of November 28, 2006

Current State and Date of Incorporation or Registration: Nevada, 10/12/2005,
Standing in this jurisdiction: (e.g. active, default, inactive): Active and In Good Standing

Prior Incorporation Information for the issuer and any predecessors during the past five years:

[1] "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

`

N/A

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

Address of the issuer's principal executive office:

US:
1453 Market Street
Tallahassee, FL, 32312
Canada:
1235 Bay Street, Suite 502 (7th Floor mail delivery)
Toronto, ON Canada M5R 3 K4

The address(es) of the issuer's principal places of business:
Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

2) Security Information

Transfer Agent

Name:	Securities Transfer Corporation
Phone:	469.633.0101
Email:	smith@stctransfer.com
Address:	2901 Dallas Pkwy., Suite 380, Plano, TX 75093

Publicly Quoted or Traded Securities:

Trading symbol:	PFSF	
Exact title and class of securities outstanding:	Common Stock	
CUSIP:	69482P 205	
Par or stated value:	$0.001	
Total shares authorized:	1,950,000,000	as of date: 03/31/2026
Total shares outstanding:	773,446,598	as of date: 03/31/2026
Total number of shareholders of record:	197	as of date: 03/31/2026

Other classes of authorized or outstanding equity securities:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Trading symbol:	N/A
Exact title and class of securities outstanding:	Preferred Stock – Series A
CUSIP:	N/A
Par or stated value:	$0.001
Total shares authorized:	3,000,000 as of date: 03/31/2026
Total shares outstanding:	0 as of date: 03/31/2026

Trading symbol: N/A

`

Exact title and class of securities outstanding:	Preferred Stock – Series B
CUSIP:	N/A
Par or stated value:	$0.10
Total shares authorized:	22,000 as of date: 03/31/2026
Total shares outstanding:	0 as of date: 03/31/2026

Trading symbol:	N/A
Exact title and class of securities outstanding:	Preferred Stock – Series C
CUSIP:	N/A
Par or stated value:	$0.001
Total shares authorized:	101 as of date: 03/31/2026
Total shares outstanding:	101 as of date: 03/31/2026

Trading symbol:	N/A
Exact title and class of securities outstanding:	Preferred Stock – Series D
CUSIP:	N/A
Par or stated value:	$0.001
Total shares authorized:	1,600 as of date: 03/31/2026
Total shares outstanding:	0 as of date: 03/31/2026

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

No special dividends or preemption rights; one vote per share of common stock

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The Series A Convertible Preferred stock can be converted at the option of the holder into common stock for one preferred share for ten common shares. The Series A Convertible preferred shares have voting rights equal to ten votes per Series A share. Liquidation rights for one half of available proceeds. No redemption rights. Dividends are only due when declared for common stockholders and are based on an as converted basis

The Series B Convertible Preferred Stock has 3% annual dividends on stated value, payable upon anniversary date or conversion date. These shares shall rank senior to all common stock issuances and below Series A Convertible Preferred Shares. The Series B Preferred stock is convertible at the option of the holder at the lower of (i) the 25% lowest closing bid price for the 20 trading days prior to the conversion or (ii) the fixed price, which is set at $1.00 both of which are subject to adjustment as provided in the Series B Preferred certificate of designation, which creates a variable number of common shares into which the Series B shares may be converted. The Series B Preferred shares have no voting rights and there is a limit on beneficial ownership of 9.99%. Liquidation rights are pari passu with all preferred stock classes. There are no redemption rights.

The Series C Preferred Stock has no conversion rights. Its voting rights are determined by the following formula: total common stock eligible votes multiplied by .019607, divided by .49, minus outstanding common stock multiplied by .019607. The Series C stock has no liquidation or redemption rights. The shares remain outstanding until the earlier of 36 months from the authorization date or receipt of an investment of at least $10,000,000.

The Series D Preferred is not entitled to receive dividends, nor any liquidation or redemption rights. Each share of Series D shall be convertible, at the option of the holder thereof, without the payment of additional consideration, into that number of fully paid and nonassessable shares of Common Stock equal to 0.01% of the total number of shares of Common Stock outstanding at the Conversion Time. The Series D shall rank junior to the already-existing classes of the Corporation's Series Preferred stock and pari-passu with the Corporation's Common Stock. And any class or series of capital stock of the Corporation hereafter created and has no voting rights. The shares have a term of the earlier of 36 months from the authorization date or upon receipt of an investment of at least $5,000,000.

3. Describe any other material rights of common or preferred stockholders.

NONE

`

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

NONE

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: Opening Balance Date 9/30/2025. Common: 47,281,336 Preferred: 2,226,000	*Right-click the rows below and select "Insert" to add rows as needed.								
Date of Transaction	**Transaction type (e.g. new issuance, cancellation, shares returned to treasury)**	**Number of Shares Issued (or cancelled)**	**Class of Securities**	**Value of shares issued ($/per share) at Issuance**	**Were the shares issued at a discount to market price at the time of issuance? (Yes/No)**	**Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).**	**Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided**	**Restricted or Unrestricted as of this filing.**	**Exemption or Registration Type.**
11/03/2025	New Issuance	165,161,046	Common	.12	N/A	JSH Holdings Inc. (Janet Qi)	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	189,982,810	Common	.12	N/A	AsianTree Management Inc. (Janet Qi)	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	30,527,433	Common	.12	N/A	2284821 Ontario Inc.(Angelo Pizzuto)	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	53,139,737	Common	.12	N/A	2487456 Ontario Corporation (Sopha Sun)	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	7,102,482	Common	.12	N/A	Harry Liu	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	76,098,781	Common	.12	N/A	1461565 Ontario Inc.	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	8,585,841	Common	.12	N/A	Bobby Chujie Li	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	8,585,841	Common	.12	N/A	Zhengye Sunni Zhou	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	1,633,437	Common	.12	N/A	Elizabeth Marwick	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	4,025,805	Common	.12	N/A	Joel Etienne	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	4,025,805	Common	.12	N/A	Sheree Wong	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	5,028,937	Common	.12	N/A	Lisa Liqing Zheng	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	12,332,244	Common	.12	N/A	Dr. Jian Chen	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	8,891,115	Common	.12	N/A	Bi Kim	RTO Transaction	Restricted	4(a)(2)
11/03/2025	New Issuance	5,914,690	Common	.12	N/A	Edward Wallace	RTO Transaction	Restricted	4(a)(2)
11/19/2025	New Issuance	5,863,391	Common	.02	N/A	Trillium Partners LP	Convertible Debenture	Unrestricted	
09/03/2025	New Issuance	700,000	Common	.001	N/A	David Lomedico	RTO/previous investor	Restricted	4(a)(2)
09/03/2025	New Issuance	20,000	Common	.001	N/A	TIMOTHY SIEGLER	RTO/previous investor	Restricted	4(a)(2)
09/03/2025	New Issuance	1,000,000	Common	.001	N/A	ROBERT SCHIESTL	RTO/previous investor	Restricted	4(a)(2)

09/03/2025	New Issuance	66,667	Common	.001	N/A	MARVIN BERLIN	RTO/previous investor	Restricted	4(a)(2)
09/03/2025	New Issuance	3,600,000	Common	.001	N/A	JAMES C DIPRIMA	RTO/Shares for service	Restricted	4(a)(2)
09/03/2025	New Issuance	1,666,667	Common	.001	N/A	JASON COHEN	RTO/previous investor	Restricted	4(a)(2)
09/03/2025	New Issuance	1,500,000	Common	.001	N/A	LASANDRE MORRIS	RTO/Shares for service	Restricted	4(a)(2)
09/03/2025	New Issuance	500,000	Common	.001	N/A	ALAN STONE & COMPANY LLC	RTO/Shares for service	Restricted	4(a)(2)
09/03/2025	New Issuance	50,000	Common	.001	N/A	SEAN D SIMPSON	RTO/previous investor	Restricted	4(a)(2)
09/03/2025	New Issuance	176,667	Common	.001	N/A	ROY EWEN	RTO/previous investor	Restricted	4(a)(2)
09/03/2025	New Issuance	50,000	Common	.001	N/A	RANDAL SEEWALD & LISA SEEWALD	RTO/previous investor	Restricted	4(a)(2)
01/31/2026	New Issuance	2,800,000	Common	.001	N/A	Lomedico and Associates	Pref A Conversion	Restricted	4(a)(2)
01/31/2026	New Issuance	12,510,290	Common	.001	N/A	HARRYSEN MITTLER	Pref A Conversion	Restricted	4(a)(2)
01/31/2026	New Issuance	3,149,710	Common	.001	N/A	PETER PIZZINO	Pref A Conversion	Restricted	4(a)(2)
01/31/2026	New Issuance	1,000,000	Common	.001	N/A	JAMES C DIPRIMA	Pref A Conversion	Restricted	4(a)(2)
01/31/2026	Cancellation	(2,226,000)	Pref Series A	.001	N/A	N/A (see list above)	Pref A Conversion (Per RTO)		
01/31/2026	Cancellation	(1,000)	Pref Series B	.10	N/A	HARRYSEN MITTLER	Pref A Conversion (Per RTO)		
01/31/2026	Cancellation	(6,191,781)	Common	.001	N/A	MALCOLM LEISSRING	Per agreement – did meet full obligation		
01/31/2026	Cancellation	(2,500,000)	Common	.001	N/A	CBG Associates LLC	Per agreement – did meet full obligation		
01/31/2026	Cancellation	(1,500,000)	Common	.001	N/A	Regents of the University of California	Per agreement – did meet full obligation		
01/29/2026	New Issuance	7,244,948	Common	.02	N/A	Trillium Partners LP	Convertible Debenture	Unrestricted	
02/23/2026	New Issuance	13,520,252	Common	.02	N/A	Alpha Capital Anstalt	Convertible Debenture	Restricted	4(a)(2)
02/09/2026	New Issuance	18,501,609	Common	.12	N/A	JSH Holdings Inc. (Janet Qi)	RTO Transaction	Restricted	4(a)(2)
02/09/2026	New Issuance	21,279,854	Common	.12	N/A	AsianTree Management Inc. (Janet Qi)	RTO Transaction	Restricted	4(a)(2)
02/09/2026	New Issuance	3,416,490	Common	.12	N/A	2284821 Ontario Inc.(Angelo Pizzuto)	RTO Transaction	Restricted	4(a)(2)
02/09/2026	New Issuance	1,381,614	Common	.12	N/A	Dr. Jian Chen	RTO Transaction	Restricted	4(a)(2)
02/09/2026	New Issuance	998,666	Common	.12	N/A	Bi Kim	RTO Transaction	Restricted	4(a)(2)
02/09/2026	New Issuance	660,772	Common	.12	N/A	Edward Wallace	RTO Transaction	Restricted	4(a)(2)
03/18/2026	New Issuance	27,076,552	Common	.0415	N/A	Pang Yen Chen	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	3,616,637	Common	.0415	N/A	Chen Yu Chen	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	120,796	Common	.0415	N/A	Wang Chien Wen	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	6,329,114	Common	.0415	N/A	Chien Li Jen	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	39,793	Common	.0415	N/A	Nai Hui Lin	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	361,664	Common	.0415	N/A	Hsiao Chi	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	72,333	Common	.0415	N/A	Zhang-Xi Huang	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	144,665	Common	.0415	N/A	Dr Chau	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	1,699,819	Common	.0415	N/A	Huang Shih Chi	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	1,666,265	Common	.0415	N/A	Po Hua Su	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	4,219,409	Common	.0415	N/A	Chien Wei Chen	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	241,109	Common	.0415	N/A	Wei-Yi Kong	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	482,242	Common	.0415	N/A	Jian-Yu Wang	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	964,436	Common	.0415	N/A	Wei Wang	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	723,327	Common	.0415	N/A	Chen, Mao-Chen (Ethan)	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	964,919	Common	.0415	N/A	Hsu, Yu-Chen	Reg S	Restricted	4(a)(2)

`

03/18/2026	New Issuance	1,717,902	Common	.0415	N/A	Robert Weir	Reg S	Restricted	4(a)(2)
03/18/2026	New Issuance	343,580	Common	.0415	N/A	Christine Weir	Reg S	Restricted	4(a)(2)
03/31/2026	New Issuance	3,000,000	Common	.0001	N/A	Alan Kosikowski	Per consulting agreement	Restricted	4(a)(2)

Shares Outstanding: Balance_sheet date:

Date 03/31/2026 Common: 773,446,598

Preferred Stock

Series A: 0

Series B: 0

Series C: 101

Series D: 0

Note on Share Redemptions and Capital Structure Alignment (Recognized During the Period)

During the reporting period ended March 31, 2026, the Company completed the administrative processing for the recapitalization of its capital structure to align with the post-RTO business model. As of January 31, 2026, all legacy dilutive items—with the exception of the SAFE Investment—were fully resolved through share conversions, redemptions, or cancellations.

Specifically, the redemption and surrender of Series A Preferred Stock was finalized, and the common stock ledger was updated to reflect the formal cancellation of 1,500,000 shares returned following the Dreamaderm transaction termination. Third-party legacy debt balances (excluding the SAFE investment) were fully converted or settled as part of this recapitalization phase to establish an accurate and clean cap table for PurMinds Enterprises, Inc.'s ongoing business operations.

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance ($)	Principal Amount at Issuance ($)	Interest Accrued ($)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
03/31/2023	5,968,999	5,968,999	0.00	N/A	SAFE Investment	PurMinds Holdings' list of 12 investors	Original investors

Note Modification and Settlement Disclosures:

- **Debt Assignment & Forgiveness:** On April 1, 2023, Alpha Capital Anstalt and Oscaleta Partners LLC partially forgave outstanding debt balances. Oscaleta Partners LLC subsequently assigned its remaining principal and interest to Frondeur Partners LLC during the quarter ended June 30, 2023.
- **Final Settlement Date:** The entire transaction was fully completed as of February 9, 2026.
- **Total Value & Entities Extinguished:** A total of $300,000 in convertible debentures plus accrued interest was fully settled, completely satisfying all remaining note liabilities tied to **Alpha Capital Anstalt, Oscaleta Partners LLC, Trillium Partners LP, and Frondeur Partners LLC**.
- **Equity Conversion:** The liabilities were converted at a fixed price of $0.02 per share, resulting in the issuance of 26,628,590 common shares.
- **ITA Status:** All associated Irrevocable Transfer Agent Instructions (ITAI) have been satisfied, closed out, and removed from the transfer agent's records.

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

`

On August 19, 2025, the Company entered into a stock purchase agreement with PurMinds Holdings Inc., which owns all outstanding shares of 10763942 Canada Inc., a clinical-stage neuromedicine company. The transaction was completed on November 3, 2025. Accordingly, these financial statements reflect that transaction and have been recast to present the business of the accounting acquirer.

The corporate name change to PurMinds Enterprises, Inc. has been approved by the State of Nevada. The Company currently continues to trade under the legal name Pacific Software, Inc. while the related name and ticker symbol change applications are being processed by FINRA.

PurMinds Enterprises, Inc. is a neuromedicine company focused on neurological and psychiatric conditions through a precision medicine approach. Its strategy is intended to support long-term value creation through the development of therapeutics that target neuroplasticity and neuromodulation, while also pursuing shorter- and medium-term commercial opportunities in diagnostics and care programs based on a predictive, preventive, personalized, and participatory care model.

B. List any subsidiaries, parents, or affiliated companies.

<u>Active:</u>
10763942 Canada Inc. – (CDA Corp.) – Operating Entity
Purplante BioScience Inc. – (CDA Corp.)
<u>Inactive:</u>
PurMinds (US) Inc. (US - DE)
PurPlante Technology Inc. (US - DE)
BioScience PurSolutions Inc.(CDA-QC)
Therapeutique PurQuest Inc. (CDA-QC)

C. Describe the issuers' principal products or services and their markets.

The Company is currently pre-revenue. Its business plan is focused on the following product and service areas:

Products & Services Description

1. Precision Neuro-Therapeutics (Drug Pipeline)

PurMinds is developing a pipeline of neuroplastogen and neuroprotective compounds intended to address neuronal impairment associated with inflammation and degeneration:

- **Botanical Drug Development (PUR100 Series):** The Company continues to actively advance its proprietary botanical formulations targeting high-need indications, including anxiety in oncology and palliative care. Under an active Know-How License Agreement, the Company successfully deployed an initial funding payment of **$100,400** to a world-renowned U.S. medical research institution to establish essential project start-up infrastructure and move the pipeline into active clinical phases. This strategic capital deployment was allocated across the following operational categories:
    - Clinical Protocol & Regulatory Infrastructure: Funds dedicated to protocol development, institutional review board (IRB) review, and core start-up efforts.
    - Operational & Technical Setup: Allocation toward specialized pharmacy setup, clinical research translation unit infrastructure, and data management system (RAVE) builds.
    - Analytical Implementation: Capital designated to fulfill baseline statistical implementation and initial maintenance fees.
- **Novel Neuroplastogens (PUR500 Series):** Featuring lead candidate **PUR501**, a first-in-class small molecule designed to promote neuroplasticity without the hallucinogenic effects or cardiovascular risks of traditional psychoactive compounds.
- **Specialty API Supply:** Global supply of pharmaceutical-grade compounds for global clinical research and commercial use under a **Health Canada Controlled Drugs and Substances License**.

2. Next-Generation Diagnostics & Early Detection

Through an exclusive partnership and strategic alliance with SpectroChip Global Inc., a privately held company, PurMinds is working to commercialize a photonic chip diagnostic platform. As part of this commercialization effort, the Company had provided a strategic investment of **$699,881** as of March 31, 2026.

- **Point-of-Care Testing (POCT):** Portable diagnostic tools offering hospital-grade accuracy for early detection of neurological conditions, such as dementia, years before clinical symptoms manifest.
- **At-Home Molecular Tools:** Development of low-cost, high-sensitivity diagnostic kits for infectious diseases and biological threats.
- **Current Investment and Licensing Status:** As of the close of the current reporting period, the Company maintained a balance of **$699,881** and will continue to invest. In addition to this balance, the Company has successfully initiated payments toward its **$500,000** strategic licensing fee obligation. Under the terms of the underlying agreement, the fee is split into two equal tranches of **$250,000**. The **first** installment of **$250,000** was fully funded and paid on March 31, 2026 , and the final matching payment of **$250,000** was completed in May 2026, completely satisfying the licensing fee liability.

`

- **FDA & Regulatory Roadmap:** Our commercialization timeline is synchronized with SpectroChip's current regulatory activities.

3. Specialized GMP Operations
PurMinds utilizes its proprietary R&D and manufacturing capabilities to scale the production of nature-inspired neuroprotective compounds and precision medicine tools for global distribution, with a strategic focus on high-growth markets in **the U.S., Asia, Europe, and the Middle East**.

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and to the extent to which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company operates a 20,477 sq. ft. pharmaceutical manufacturing and research facility situated on 1.4 acres of land. The site is configured for the production of solid-dose pharmaceuticals in accordance with current good manufacturing practice standards.

- **Infrastructure & Standards:** All facility improvements are less than two years old and meet **ISO 8 clean room** standards.
- **Advanced Security:** The site features two in-process secure GMP suites protected by password-access controls and **seismic sensors**. The warehouse includes a specialized secure cage and vault for the storage of controlled materials.
- **Operational Redundancy:** A dedicated, fully equipped machine shop is located on-site for immediate repairs. The facility previously held a Drug License, Standard Processing License, and a Drug Establishment License (DEL).
- **ESG & Logistics:** The exterior includes a fully renovated parking area with **six electric vehicle (EV) charging stations**, ensuring sustainable operations.**Officers, Directors, and Control Persons**

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more that 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Name of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Janet Qi.	>5%, CEO, Director	Toronto, ON Canada	381,643,494 101	Common Stock Series C Preferred Stock	42.12% 100%	
Angelo Pizzuto	>5%	Vaughan, ON Canada	42,741,957	Common Stock	4,62%	

`

A. On August 23, 2023, Izak On resigned as an Officer and Director of the Company. Mr. On also surrendered and cancelled his 50 shares of Series C Preferred Stock, as part of his resignation.

B. On September 22, 2023, Ryan Sherman resigned as an Officer and Director and surrendered 51 shares of Series C Preferred Stock for cancellation. Concurrently, James DiPrima was appointed Chief Financial Officer and Secretary, and Harrysen Mittler was appointed Chief Executive Officer and Director.

C. On October 14, 2025, Janet Qi, Angelo Pizzuto and Sheree Wong were appointed to the Board.

D. Mr. Harrysen Mitler resigned November 21, 2025, as CEO of the Company and appointed Ms. Janet Qi, CEO, and Chairwomen.

E. Effective May 2, 2026, James DiPrima resigned from his position as Chief Financial Officer (CFO) of the Company. Concurrently, Angelo Pizzuto was appointed as Chief Financial Officer. Mr. Pizzuto will serve in this capacity alongside his existing roles as Secretary and Treasurer of the Company. The resignation of Mr. DiPrima was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices**.**

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the people or entities listed above in Section 6 have, <u>in the past 10 years</u>:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations).

<u>NONE</u>

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities.

<u>NONE</u>

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated.

<u>NONE</u>

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

<u>NONE</u>

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

<u>NONE</u>

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

<u>NONE</u>

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis

`

alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

8) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel
Name: Tomer Tal
Firm: New Venture Attorneys and Investors Counsel Attorneys
Address 1: 1325 Airmotive Way, Suite 202
Address 2: Reno, NV 89502
Phone: 408.313.8130
Email: tomer@newventureattorneys.com

Accountant or Auditor (PCAOB Auditor)
Name: Tommy Shek, CPA
Partner, Audit & Assurance Services/Accounting Advisory Services
Firm: TAAD, LLP
Address 1: 20955 Pathfinder Road, Suite 370,
Address 2: Diamond Bar, CA 91765, USA
Phone : 626.327.2788
Email : tommy@taadllp.com

Investor Relations
Name: Scott Powell
President & CEO
Firm: Skyline Corporate Communications Group, LLC
Address: Americas Tower
1177 Avenue of the Americas, 5th Floor
New York, NY 10036 USA
Email: scott@skylineccg.com
Website: www.skylineccg.com

Other Service Providers

NONE

9) Financial Statements

A. This Disclosure Statement was prepared by (name of individual):

Name: Angelo Pizzuto
Title: CFO, Secretary & Treasurer
Relationship to Issuer: Officer, Director

B. The following financial statements were prepared in accordance with:

☒ U.S. GAAP (see Note 1B Basis of Accounting)
☐ IFRS

C. The following financial statements were prepared by (name of individual):
Name: Angelo Pizzuto
Title: CFO, Secretary-Treasurer
Relationship to Issuer: Officer, Director
Describe the qualifications of the person or persons who prepared the financial statements:[5]

[5] The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

`

<u>30 Years of Private Accounting, as well as 12+ years in corporate finance and fractional CFO services.</u>

Provide the following qualifying financial statements:

a. Audit letter, if audited.
b. Balance Sheet.
c. Statement of Income.
d. Statement of Cash Flows.
e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
f. Financial Notes

<u>Financial Statement Requirements</u>:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, <u>Janet Qi</u> certify that:

1. I have reviewed this Disclosure Statement for <u>Pacific Software, Inc</u>.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: May 20, 2026

By: /s/ Janet Qi

Janet Qi

Chief Executive Officer

`

Principal Financial Officer:

I, Angelo Pizzuto certify that:

1. I have reviewed this Disclosure Statement for Pacific Software, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: May 20, 2026

By: /s/ Angelo Pizzuto

Angelo Pizzuto

Chief Financial Officer

`

FINANCIAL STATEMENTS

Index to the Condensed Consolidated Financial Statements (Unaudited)

Note on Supplemental Disclosures and Compliance

1. Shell Status and Change in Control As of March 31, 2026, the Company is not a shell company. A change in control occurred on November 3, 2025, following the acquisition by PurMinds Holdings Inc. of 100% of 10763942 Canada Inc. The related cover page disclosures have been marked to reflect that status.

2. Share Capital Reconciliation The Company has verified that the common shares outstanding as of March 31, 2026, total **773,446,598**. All typographical errors regarding the shareholder record date (previously listed as 03/31/2026) and share count discrepancies between sections have been corrected to ensure consistency across the disclosure.

3. Basis of Presentation and Going Concern (US GAAP) These financial statements are prepared in accordance with U.S. GAAP. The Company has incurred recurring losses and has a working capital deficit of ($2,184,297) as of the reporting date. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans to address this include the pursuit of additional equity and debt financing. The financial statements do not include adjustments that might result from the outcome of this uncertainty.

4. Reverse Takeover (RTO) Accounting In accordance with ASC 805, the financial statements for the comparative period ending March 31, 2025 and September 30, 2025, have been recast to represent the financial history of the accounting acquirer (10763942 Canada, Inc. (aka PurMinds NeuroPharma)) rather than the legal shell.

5. Officer Certification The signatures provided by the CEO and CFO in the Certification section of this report follow the digital signature format **/s/** as required by OTC Markets and SEC guidelines.

Note regarding Subsequent Share Redemptions and Cap Table Adjustments

Subsequent to the reporting period ending March 31, 2026, the Company has initiated the final administrative processing for the recapitalization of its capital structure following the November 3, 2025 Reverse Takeover (RTO).

As of January 31, 2026, the redemption of Series A Preferred Stock and the final adjustments to the common stock ledger—including the formal cancellation of shares returned following the Dreamaderm transaction termination—will be fully completed.

These adjustments will align the Company's internal ledger with the figures reported in this disclosure, ensuring a finalized and accurate cap table for the PurMinds Enterprises, Inc. business operations.

`

PACIFIC SOFTWARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT MARCH 31, 2026 & 2025 (Recasted) SEPTEMBER 30, 2025 (Recasted)
(Unaudited)

(Currency: USD)	6 mths Year Ended March 31, 2026	6 mths Year Ended March 31, 2025 **(Recasted)**	12 mths Year Ended September 30, 2025 **(Recasted)**
Current Assets:			
Cash and cash equivalents	$16,719	($11,693)	$311
Prepaid expenses and other current assets	325,155	295,190	155,974
Total current assets	341,874	283,497	156,285
Non-Current Assets:			
Property and equipment, net	15,185	1,913,302	27,189
Intangible assets, net (Patents)	59,258	52,824	55,734
Other assets - Investment SpectroChip Global Inc.	699,881	0	0
Total Assets	**$1,116,198**	**$2,249,623**	**$239,208**
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current Liabilities:			
Accounts payable	$741,306	$589,666	$789,091
Accrued expenses and payroll liabilities	745,608	458,113	783,738
Convertible debentures, current (3rd Party)	0	300,000	300,000
Notes payable, 3rd party (Current)	1,039,257	957,691	1,019,921
Notes payable, related party (Current)	0	0	0
Total current liabilities	2,526,171	2,305,470	2,892,750
Long-term Liabilities:			
Convertible debentures, net (3rd Party)	310,062	413,704	424,531
Notes payable, 3rd party (Long-term)	0	0	0
Notes payable, related party (Long-term)	1,145,834	1,097,303	1,159,775
SAFE liability	5,968,999	5,968,999	5,968,999
Total Liabilities	7,424,895	7,480,006	7,553,305
Stockholders' Equity:			
Preferred stock; Series A ($0.001 par value)	0	1,613	2,226
3,000,000 shares authorized, par value $.001			
Preferred stock; Series B ($0.001 par value)	0	200	100
preferred stock, 22,000 shares authorized, par value $0.10			
Preferred stock; Series C ($0.001 par value)	0	0	0
101 shares authorized, par value $0.001			
Preferred stock; Series D ($0.001 par value) 1,600 shares authorized, par value $0.001	0	0	0
Common stock ($0.001 par value)	773,447	40,034	47,281
1,950,000,000 shares authorized, par value $0.001			
Stock Subscriptions Received	40,000	0	0
Common stock ($0.001 par value)			
Additional paid-in capital	32,485,150	30,508,871	30,565,085
Accumulated deficit	(42,280,026)	(38,129,614)	(40,318,212)

`

Accumulated other comprehensive loss (FX)	146,561	43,043	(503,327)
Total stockholders' equity	(8,834,869)	(7,535,853)	(10,206,847)
Total Liabilities and Stockholders' Equity	**$1,116,198**	**$2,249,623**	**$239,208**

The accompanying notes are an integral part of these consolidated financial statements.

`

PACIFIC SOFTWARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS, MARCH 31, 2026 & 2025 SEPTEMBER 30, 2025
(Unaudited)

(Currency: USD)	3 mths	3 mths	6 mths	6 mths	12 mths
Description	Year Ended March 31, 2026	Year Ended March 31, 2025 **(Recasted)**	Year Ended March 31, 2026	Year Ended March 31, 2025 **(Recasted)**	Year Ended September 30, 2025 **(Recasted)**
Revenue	$0	$0	$0	$0	$0
Cost of Goods Sold	0	0	0	0	0
Gross Profit	**0**	**0**	**0**	**0**	**0**
Operating Expenses:					
Research & Development, Licensing fees	(350,400)	0	(350,400)	(672)	(6,572)
Professional, Legal and Audit Fees	(96,428)	(38,493)	(168,887)	(161,397)	0
General and Administrative	(345,842)	(227,365)	(659,144)	(570,297)	(738,778)
Depreciation and Amortization	(6,102)	(48,193)	(12,099)	(97,636)	(148,267)
Loss on Disposal of Assets *(Terminal Loss)*	0	0	0	0	(1,885,648)
Transaction Costs:RTO, Capital Markets Fees	(15,000)	0	0	0	0
Total Operating Expenses	(813,772)	(314,051)	(1,190,530)	(830,002)	(2,779,265)
Loss from Operations	**(813,772)**	**(314,051)**	**(1,190,530)**	**(830,002)**	**(2,779,265)**
Other Income / (Expense):					
Government Grant Income and Other Income/(Expense)	(107,827)	132,080	(106,891)	150,832	37,128
Interest Income / (Expense)	0	0	0	0	(546,640)
Total Other Income/(Expense), net	(107,827)	132,080	(106,891)	150,832	(509,512)
Net Income (Loss)	($921,600)	($181,971)	($1,297,421)	($679,170)	($3,288,776)
Net Loss Per Share:					
Basic	($0.00)	($0.00)	($0.00)	($0.02)	($0.07)
Diluted	($0.00)	($0.00)	($0.00)	($0.02)	($0.07)
Weighted Avg Shares:					
Basic	773,446,598	40,032,889	773,446,598	40,032,889	47,281,336
Diluted	773,446,598	40,032,889	773,446,598	40,032,889	47,281,336

The accompanying notes are an integral part of these consolidated financial statements.

`

PACIFIC SOFTWARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT
For the Six months ended March 31, 2026
(Unaudited)

	PREFERRED SHARES						Common Shares		Additional Paid-In Capital	Accumulated Deficit
	Series A Amount	Series A Value ($)	Series B Amount	Series B Value ($)	Series C Amount	Series C Value ($)	Amount	Value ($)	Value ($)	Value ($)
Balance December 31, 2024	1,613,000	$1,613.00	1,000	$100.00	101	$0.10	47,281,336	$47,281.34	$29,055,614	($29,581,013)
Acquisition										
Net Loss										($1,843)
Balance March 31, 2025	**1,613,000**	**$1,613.00**	**1,000**	**$100.00**	**101**	**$0.10**	**47,281,336**	**$47,281.34**	**$29,055,614**	**($29,582,856)**
Issuance: Series A shares for settlement	167,000	$167.00								
Net Loss										($968)
Balance June 30, 2025	**1,780,000**	**$1,780.00**	**1,000**	**$100.00**	**101**	**$0.10**	**47,281,336**	**$47,281.34**	**$29,055,614**	**($29,583,824)**
Issuance: Series A shares for settlement	446,000	$446.00							($99,695)	$177,134
Net Loss										($311,579)
Balance September 30, 2025	**2,226,000**	**$2,226.00**	**1,000**	**$100.00**	**101**	**$0.10**	**47,281,336**	**$47,281.34**	**$28,955,919**	**($29,718,269)**
ITAI -Issuance							5,863,391	$5,863.39	$111,404	
RTO - Issuance - PurMinds Group							581,036,004	$581,036.00	$1,031,672	($11,543,544)
RTO - Issuance - Original Shareholders per RTO							9,320,002	$9,320.00	($9,037)	
Net Loss										($67,730)
Balance December 31, 2025	**2,226,000**	**$2,226.00**	**1,000**	**$100.00**	**101**	**$0.10**	**643,500,733**	**$643,500.73**	**$30,089,958**	**($41,329,543)**
Pref A Conversion	(2,226,000)	($2,226.00)	(1,000)	($100.00)			19,460,000	$19,460.00	$17,234	
Adjustments/Cancellation per RTO							(10,191,781)	($10,191.78)	($10,192)	
ITAI -Issuance (TP)							7,244,948	$7,244.95	$137,654	
ITAI -Issuance (ACA)							13,520,252	$13,520.25	$256,885	
PurMinds Investor's (ND)							46,239,007	$46,239.01	$1,939,937	$346,938
Reg S (TWN and CDA)							50,673,440	$50,673.44	$50,674	
Consulting Agreement (AK)							3,000,000	$3,000.00	$3,000	
Net Loss										($1,297,421)
Balance March 31, 2026	**0**	**$0.00**	**0**	**$0.00**	**101**	**$0.10**	**773,446,598**	**$773,446.60**	**$32,485,150**	**($42,280,026)**

`

PACIFIC SOFTWARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026
(Unaudited)

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the related notes contained within this report. Our financial statements have been prepared in accordance with U.S. GAAP and reflect the corporate reorganization following our Reverse Takeover transaction.

A. Executive Overview & Recent Corporate Restructuring

On November 3, 2025, the Company successfully closed a Reverse Takeover ("RTO") transaction with PurMinds Holdings Inc. (including its wholly owned operating subsidiary, 10763942 Canada Inc., dba PurMinds NeuroPharma), a clinical-stage neuromedicine company. This milestone transaction established a new control group, an updated executive management team, and entirely shifted our corporate mandate toward the advancement of a proprietary neurological drug pipeline and advanced diagnostic applications.

To systematically align our capital structure and resource allocation with our new clinical business model, management executed an aggressive operational and balance sheet cleanup at the public shell level during the period. This capitalization optimization phase successfully achieved the formal cancellation and return of 1,500,000 legacy common shares stemming from the terminated Dreamaderm transaction, the complete redemption and retirement of all outstanding Series A Preferred stock, and the cancellation of 1,000 Series B Preferred shares. Concurrently, the Company finalized the complete settlement and elimination of $300,000 in legacy promissory note liabilities alongside the formal termination of a historical executive contract.

Consequently, as of March 31, 2026, the Company's legacy shell obligations have been systematically cleared, presenting a significantly cleaner corporate balance sheet. Moving forward, management continues to aggressively review and optimize outstanding liabilities at the operating company level to further streamline the consolidated debt profile and preserve equity value.

B. Results of Operations

For the three and six months ended March 31, 2026, the Company generated $0 in revenue, consistent with our progression as a pre-revenue, clinical-stage biotechnology entity. Total operating expenses for the six months ended March 31, 2026, were $1,190,530, compared to a recasted historical comparative baseline of $830,002 for the six months ended March 31, 2025. This planned expansion in operational expenses directly reflects the heightened infrastructure requirements, licensing fees, and R&D pipelines brought on by the active PurMinds operating business.

The primary drivers of our current six-month operating costs include:

- **General and Administrative (G&A):** $659,144, representing corporate overhead, international management costs, and entity consolidation. In accordance with **U.S. GAAP ASC 350-50**, this line item also includes $20,000 allocated for corporate website development, infrastructure deployment, and marketing content. Per accounting guidelines, because these expenditures relate to launch-stage digital positioning, public branding, and continuous operational deployment rather than internal-use software capitalization, they have been fully expensed within the current reporting period.
- **Research and Development (R&D):** $350,400, invested directly into advancing our clinical pipeline and diagnostic platforms. This allocation consists of a **$250,000 licensing fee paid to SpectroChip Global Inc.** for our photonic chip diagnostic platform rights, and **$100,400 allocated to a premier U.S. clinical research institution** for collaborative neuromedicine programs.
- **Professional and Audit Fees:** $168,887, allocated toward legal restructuring, compliance counsel, and audit readiness.

Net Loss for the six-month period was $1,297,421. Operating results for the period reflect a non-recurring adjustment/expense of $106,891 stemming from the final administrative conclusion of a regulatory government audit of our historical Scientific Research and Experimental Development (SR&ED) tax credits. While this audit finalization resulted in a 50% reduction against our initial legacy estimated asset baseline, management successfully defended and secured the remaining substantial portion of the claim. This finalized resolution successfully solidifies a significant, non-dilutive capital recovery flowing into our Canadian operating infrastructure, completely clearing historical tax credit contingencies moving forward.

`

C. Liquidity and Capital Resources

As of March 31, 2026, the Company's consolidated cash and cash equivalents totaled exactly $16,719. Reflecting our post-RTO operational alignment, these treasury assets are centrally maintained within our Canadian operating subsidiary, 10763942 Canada Inc. (dba PurMinds NeuroPharma), at a Tier-1 financial institution.

Under this structure, 10763942 Canada Inc. functions as the core treasury and centralized funding vehicle for the entire consolidated organization. Rather than dispersing small cash balances across multiple entity bank accounts, the Canadian operating unit directly manages and deploys this capital to advance local clinical research, while concurrently serving as the "banker" responsible for clearing administrative overhead, transfer agent fees, and public regulatory compliance obligations for the U.S. parent shell.

While our cash on hand at the period-end date reflects immediate localized operational staging, our long-term capital runway and post-RTO milestones have been heavily fortified through highly successful private placement tranches under Regulations S and D of the Securities Act of 1933:

1. **March 2026 (During the Quarter):** The Company closed an additional $2,101,781 in cash proceeds through a Regulation S placement. Concurrently, $40,000 in cash was accepted from investors under Regulation D, which has been appropriately recorded as *Stock Subscriptions Received* within the equity section pending final administrative issuance by our Transfer Agent.
2. **Subsequent Capital Receipts (Post-March 31 Through May 20, 2026):** Demonstrating strong institutional and private investor confidence, the Company secured an additional **$428,037** in cash proceeds under Regulation S and **$125,000** under Regulation D subsequent to the quarter close.

Total private capital raised or formally committed since the inception of the RTO has exceeded $2.25 million. Management intends to leverage these resources alongside an additional $1,000,000 in "circled" private interest currently being finalized from accredited groups to bridge into subsequent funding tranches targeting up to $20 million to fully fund our long-term clinical roadmap.

To further institutionalize our fundraising architecture and support long-term clinical pipeline expansion, management is actively evaluating strategic engagements with specialized institutional investment groups and capital advisory firms to structure and execute upcoming Tier-2 Regulation A+ and institutional Regulation D multi-million dollar capital raises. These planned structured offerings are intended to systematically scale our capital runway, broaden our accredited and institutional shareholder base, and fund our targeted clinical milestones over the next 24 months.

D. Off-Balance Sheet Arrangements

As of March 31, 2026, the Company does not maintain any off-balance sheet arrangements, variable interest entities (VIEs), structured finance mechanisms, or specialized derivative relationships that have, or are reasonably likely to have, a current or future material effect on our financial health, operational costs, or capital deployment tables.

E. Plan of Operations & Key Strategic Milestones

Moving deeper into fiscal year 2026, management is strictly execution-focused, moving past corporate restructuring and entering a high-growth public market phase. Our milestones over the next 12 months consist of:

- **Start of the PCAOB Audit:** On May 5, 2026, the Company formally launched its PCAOB-level audit. To accelerate this compliance pathway and minimize standard auditing friction, we engaged an independent, professional pre-audit accounting preparation firm to optimize our records prior to final delivery to our principal PCAOB audit team. **The entire audit process is expected to be completed by the end of June or early July 2026.** This milestone is a strict regulatory requirement to support our planned up-listing application to the OTCQB or OTCQX tiers.
- **FINRA Form 211 Submission:** Immediately upon the sign-off and publication of our PCAOB-audited financials, the Company will coordinate with an institutional Market Maker to submit a Rule 15c2-11 application with FINRA. This will permanently remove any lingering shell restrictions and re-establish a transparent, robust public quote under our newly approved corporate identity, PurMinds Enterprises, Inc.
- **Diagnostic Alliance Execution:** We are actively moving forward with our strategic alliance with SpectroChip Global Inc. to drive commercialization pathways for our proprietary diagnostic platforms.

`

PACIFIC SOFTWARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS
FOR THE SIX MONTHS ENDED MARCH 31, 2026 & 2025
(Unaudited)

(Expressed in US Dollars)	6 mths	6 mths
	October 1, 2025 to March 31, 2026	October 1, 2024 to March 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Loss	($1,297,421)	($679,170)
Adjustments to reconcile Net Loss to Net Cash:		
Depreciation and Amortization	12,099	97,636
Foreign exchange	209,988	275,523
Changes in operating assets and liabilities:		
(Increase) decrease in Prepaid expenses and other assets	(169,181)	(29,965)
Increase (decrease) in Accounts payable	(47,785)	151,640
Increase (decrease) in Accrued expenses and payroll liabilities	(38,130)	287,495
Net cash used in operating activities	**(1,330,430)**	**103,159**
CASH FLOWS FROM INVESTING ACTIVITIES		
Increase in Intangible assets (Patents)	(3,524)	(6,434)
Increase in Other assets - Investment (SpectroChip)	(699,881)	
Net cash used in investing activities	**(703,405)**	**(6,434)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from Issuance of Common Stock (Reg S/D)	2,141,781	
Proceeds from Convertible debentures (3rd Party)	(114,469)	(103,642)
Proceeds from Notes payable (3rd Party)	19,336	(218,434)
Proceeds from Notes payable (Related Party)	(13,941)	48,531
Net cash provided by financing activities	**2,032,707**	**(273,545)**
Effect of exchange rate changes on cash	**17,536**	**163,922**
Net increase in cash	16,408	(12,898)
Cash at beginning of period (Sept 30, 2025 and Dec 2024)	311	1,205
Cash at end of period (Dec 31, 2025 and Dec 2024)	**$16,719**	**($11,693)**

Non-cash investing and financing activities:	Shares	Value $
Conversion of convertible debentures to common stock:	26,628,590	$532,572
Debt portion		$300,000
Accrued interest portion		$232,572
Issuance of shares for RTO recapitalization:		
PER RTO - Original shareholders	18,588,221	$0
PER RTO - PurMinds Shareholders	627,275,011	$0
Consulting Agreement - Share Issuance	3,000,000	$0

The accompanying notes are an integral part of these consolidated financial statements.

`

PACIFIC SOFTWARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2026
(Unaudited)

NOTE 1 – ORGANIZATION

Pacific Software, Inc. (the "Company") was incorporated in the State of Nevada on October 12, 2005.

Note on Acquisition Reversal and Asset Disposition

Dreamaderm, Inc. Transaction Reversal
On January 23, 2024, the Company originally acquired certain assets of Dreamaderm, Inc., involving the peptide P12-3A (Dermatrix) and associated intellectual property from the University of California. However, on November 14, 2024, the Regents of the University of California terminated the acquisition.

As part of the Reverse Takeover (RTO) and recapitalization completed on November 3, 2025, this transaction was fully reversed. The 1,500,000 shares of common stock previously issued for this acquisition were returned to the Company and cancelled. Consequently, these financial statements have been adjusted to reflect the removal of Dreamaderm assets and the related equity issuance, aligning with the Company's primary focus on the PurMinds neuromedicine business model.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Management of the Company is responsible for the selection and use of appropriate accounting policies and their application. Critical accounting policies and practices are those that are both most important to the portrayal of the Company's financial condition and results and require management's most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. The Company's significant and critical accounting policies and practices are disclosed below as required by the accounting principles generally accepted in the United States of America.

Basis of Presentation/Principles of Consolidation

Historical Subsidiaries and Disposal The consolidated financial statements and related notes include the accounts of the Company and its wholly and majority-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

It should be noted that the following legacy entities were part of the Company's historical legal structure but were **divested, foreclosed upon, or otherwise removed** prior to the completion of the November 3, 2025, Reverse Takeover (RTO) and are not part of the current PurMinds business operations:

- **LLR (50.1%):** Results were included only through the foreclosure date of December 23, 2022. Following this foreclosure, the Company has no further ownership interest or liability related to LLR.
- **PAA (100%):** This entity had no assets or liabilities as of June 30, 2022, and is no longer an active part of the consolidated group.
- **Gallo (65%) and LC57 (70%):** These entities were backed out of the corporate structure as part of the pre-RTO recapitalization and asset disposition.

RTO Accounting Treatment In accordance with **ASC 805**, because the November 3, 2025, transaction is treated as a Reverse Takeover, these financial statements have been **recasted** to represent the financial history of the accounting acquirer rather than the legal shell. Consequently, the assets, liabilities, and results of operations of the legacy "backed out" entities listed above are excluded from the current consolidated balances to align with the PurMinds neuromedicine business model.

Management use of estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the valuation of derivative liabilities, the useful lives of property and equipment, and the valuation allowance for deferred tax assets. Such estimates and assumptions are subject to inherent uncertainties, and actual results could differ materially from those estimates.

`

Cash and cash equivalents

Cash includes demand deposits and short-term liquid investments with an original maturity of three months or less. As of March 31, 2026, a portion of the Company's cash is held in Canadian financial institutions by the Company's operating subsidiary **in trust** for the parent entity. These funds are being maintained in these custodial accounts pending the finalization of the Company's integrated U.S. banking structure.

Concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash accounts. As of March 31, 2026, the Company held approximately **$16,719** in cash. These deposits are maintained in a Canadian financial institution where they are insured by the **Canada Deposit Insurance Corporation (CDIC) up to $100,000 CAD**. At various times during the year, the Company's cash balances exceeded these insured limits. The Company has not experienced any losses in such accounts and believe the risk is mitigated by the stability of the Tier-1 Canadian financial institution holding the funds.

Cost of Goods Sold

Cost of goods sold consists of the costs of inventory sold, including raw materials and **direct labor costs associated with production**. The Company classifies all costs directly related to the manufacturing and formulation of its products within cost of goods sold to properly reflect gross profit.

Accounts receivable and allowance for doubtful accounts

Accounts receivables are stated at the amount management expects to collect from outstanding balances. These receivables are mostly related to credit card processing by third parties and generally remitted within three days. The Company generally does not require collateral to support customer receivables. The Company provides an allowance for doubtful accounts based upon a review of the outstanding accounts receivable, historical collection information and existing economic conditions. The Company determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management. The maximum accounting loss from the credit risk associated with accounts receivable is the amount receivable recorded, which is the face amount of the receivable net of the allowance for doubtful accounts.

Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out ("FIFO") basis. Management regularly reviews inventory quantities on hand and records a provision for excess and obsolete inventory based primarily on the estimated forecast of product demand and the ability to sell the product(s) concerned. Demand for products can fluctuate significantly. Additionally, management's estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. At March 31, 2026, and September 30, 2025, no such reserves were established.

Property and equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is currently being provided using the straight-line method for financial reporting purposes over an estimated useful life of three to twenty years. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts, and any gains or losses are credited or charged to operations in the respective periods.

Long-lived assets

In accordance with Accounting Standards Codification (ASC) Topic 360, Property, Plant, and Equipment, the Company periodically reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be realizable. An impairment loss would be recognized when estimated future cash flows are expected to result from the use of the asset and its eventual disposition is less than its carrying amount.

Other assets

Acquisition and Subsequent Reversal

On January 23, 2024, the Company entered into an agreement to acquire certain assets of **Dreamaderm Inc.**, including the peptide known as P12-3A (Dermatrix). In consideration, the Company issued 980,000 shares of Series A Convertible Preferred stock and 18,900,000 shares of common stock.

`

Termination and Exclusion from RTO
On November 14, 2024, the Regents of the University of California terminated the acquisition. Consequently, the acquisition was reversed in its entirety. As of the closing of the **Reverse Takeover (RTO) of PurMinds Holdings Inc. on November 3, 2025**, the Dreamaderm assets and related business operations were **completely backed out** of the Company's corporate structure.
Specifically:

- **Share Cancellation:** 1,500,000 shares of common stock were returned and will be cancelled by January 31, 2026.
- **Asset Removal:** No assets, intellectual property, or liabilities related to Dreamaderm Inc. or the P12-3A peptide are included in the consolidated balance sheet as of March 31, 2026.
- **Non-Core Status:** These assets were deemed non-core to the post-RTO business model of the Company (PurMinds Enterprises, Inc.) and do not form part of the continuing operations or the accounting history of the accounting acquirer.

Fair Value Measurements

The Company follows **ASC 820**, *Fair Value Measurement*, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company's financial instruments consist of cash, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of these instruments approximate their fair values due to their short-term nature.

Derivative Liabilities

The Company evaluates its financial instruments to determine if those contracts or any potential embedded components qualify as derivatives to be separately accounted for in accordance with **ASC 815-40**.
This accounting treatment requires that the carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. The change in fair value during the period is recorded as either other income or expense. Upon conversion, exercise, or repayment, the respective derivative liability is marked to fair value, and the related amount is reclassified as part of the **Gain or Loss on Extinguishment of Debt**.

As of **March 31, 2026**, and **September 30, 2025**, following the recapitalization and the Reverse Takeover (RTO) the Company has determined that there are **no material derivative liabilities** required to be recorded. All legacy derivative instruments associated with the predecessor shell were extinguished or resolved as part of the Nov 3, 2025, closing.

Convertible Notes with Fixed Rate Conversion Options

The Company may enter into convertible notes, some of which contain, predominantly, fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted by the holder into common shares at a fixed discount to the market price of the common stock at the time of conversion. This results in a fair value of the convertible note being equal to a fixed monetary amount. The Company records the convertible note liability at its fixed monetary amount by measuring and recording a premium, as applicable, on the note issuance date with a charge to interest expense in accordance with ASC 480 – "Distinguishing Liabilities from Equity".

Recognition of Revenues

The Company recognizes revenue pursuant to Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. This new revenue recognition standard (new guidance) has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied. The impact of the Company's initial application of ASC 606 did not have a material impact on its financial statements and disclosures and there was no cumulative effect of the adoption of ASC 606.

Income Taxes.

The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to be reversed. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

`

ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more likely than not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority.

Commitments and Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company's financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company's business, financial position, and results of operations or cash flows.

Stock-based compensation

The Company measures and recognizes compensation expenses for all share-based payment awards made to employees and directors, including employee stock options and compensatory stock warrants, based on estimated fair values equaling either the fair value of the shares issued or the value of consideration received, whichever is more readily determinable. Non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company's common stock at the date of the agreement.

The Company values the stock issued for compensation at the lower of the market price on the date of issuance or the value of the service provided. The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, "Equity-Based Payments to Non-Employees." The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete.

The Company has not adopted a stock option plan.

Net Income (Loss) Per Share

Basic and Diluted Loss Per Share

Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period.

Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The Company utilizes the "if-converted" method for convertible debt and preferred stock.

Anti-Dilutive Securities

For the periods ended March 31, 2026, and September 30, 2025, all potentially dilutive securities were **excluded** from the computation of diluted loss per share because their inclusion would have been anti-dilutive due to the Company's net loss position.

As of March 31, 2026, and September 31, 2025, potentially dilutive securities consisted of the following:

	March 31, 2026	September 30, 2025
Series A Preferred stock (1)	0	22,260,000
Series B Preferred stock	0	1,568,627

`

Series D Preferred stock	-	-
SAFE Investment (2)	5,968,999	5,968,999
Third party convertible debt (3)	310,062	532,572
Total	6,279,061	30,330,198

(1) Subsequent to March 31, 2026, the Series A Preferred shares were fully redeemed as part of the recapitalization.

(2) Reflects the estimated share count based on the SAFE conversion terms as of the reporting date.

(3) Includes principal and accrued interest for legacy operating entity convertible debt.

Capital Structure Recapitalization and Dilution Adjustments (Recognized During the Period)

During the reporting period ended March 31, 2026, the Company completed the final administrative processing for the recapitalization of its capital structure to align with the post-RTO business model. As of January 31, 2026, all potentially dilutive legacy items listed in the table above—with the exception of the SAFE Investment amount—have been formally resolved through a combination of share adjustments, redemptions, and cancellations.

Specifically:

- **Series A Preferred Stock:** The redemption and retirement of these shares was fully processed as of January 31, 2026, leaving a balance of zero outstanding at March 31, 2026.
- **Common Stock Ledger Adjustments:** Final updates to the common stock ledger, including the formal cancellation of 1,500,000 shares returned following the Dreamaderm transaction termination, were fully completed during the period.
- **Third-Party Debt:** Remaining convertible note balances (excluding the SAFE investment structure) were settled via conversion during the current recapitalization phase to establish a clean and accurate cap table for ongoing operations**.**
- **SAFE (Simple Agreement for Future Equity) Investment:** The **$5,968,999** SAFE amount remains outstanding as a potentially dilutive instrument as of the date of this report. It is classified as a liability because:
    - **Variable Shares:** It fails the "fixed-for-fixed" equity rule under ASC 480.
    - **Settlement:** Potential cash outflows are outside company control.
    - **Valuation:** Requires periodic fair value adjustments on the balance sheet.

  US GAAP Classification for SAFE Investments (Liability vs. Equity)
  According to **ASC 480** and **ASC 815**, SAFE investments are classified as **liabilities** rather than equity for the following reasons:
  1. Variable Share Obligation (ASC 480-10-25-14)
  2. Cash Settlement Features
  3. Derivative Treatment (ASC 815)

These adjustments ensure that the Company's internal ledger is fully aligned with the figures reported in this disclosure following the November 2025 Reverse Takeover.

Recent Accounting Pronouncements

On August 5, 2020, the Financial Accounting Standards Board (FASB) issued accounting standards update (ASU) No. 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)*.

The amendments in the ASU remove certain separation models for convertible debt instruments and convertible preferred stock that require the separation of a convertible debt instrument into a debt component and an equity or derivative component. The ASU also amends the derivative scope exception guidance for contracts in an entity's own equity. The amendments remove three settlement conditions that are required for equity contracts to qualify for the derivative scope exception.

In addition to the above, the ASU expands disclosure requirements for convertible instruments and simplifies areas of the guidance for diluted earnings-per-share calculations that are impacted by the amendments.

`

The ASU is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021. Early adoption is permitted. The FASB noted that an entity should adopt the guidance as of the beginning of its annual fiscal year. The standard is effective for the Company beginning in fiscal year September 30, 2024.

Entities may elect to adopt the amendments through either a modified retrospective method of transition or a fully retrospective method of transition. If an entity has convertible instruments that include a down round feature, early adoption of the ASU is permitted for fiscal years beginning after December 15, 2020.

ASU 2016-13 Measurement of Credit Losses on Financial Instruments and ASU 2022-02 was effective for fiscal years beginning after December 15, 2022. This adoption did not have a material effect to the Company.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

NOTE 3 – GOING CONCERN AND MANAGEMNT'S LIQUIDITY PLANS

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the six months ended March 31, 2026, the Company generated $0 in revenue, incurred a net loss of $1,297,421, and maintains an accumulated deficit of $42,280,026 alongside a working capital deficit of $2,184,297 as of the reporting date. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management's Liquidity and Capital Mitigation Plans

To systematically mitigate these going concern risk indicators, address the localized operational staging, and align our capital structure with our post-RTO business model, management has successfully executed an aggressive capital-raising strategy through private investment channels. The Company has demonstrated robust funding capabilities via private placements exempt from registration under Regulations S and D of the Securities Act of 1933.

During the six months ended March 31, 2026, the Company secured a total of $2,141,781 in cash proceeds from private investors through equity placement tranches. This capital foundation was established through an initial $1.15 million private corporate raise, followed by a subsequent private placement tranche in January 2026 that generated $834,000 in cash proceeds under Regulation S. As of March 31, 2026, the Company also accepted $40,000 in cash proceeds from private individuals under an active Regulation D offering, which has been recorded on the Balance Sheet as stock subscriptions received pending final certificate issuance.

As part of our formalized capital mitigation roadmap to eliminate our current working capital deficit, the Company is exploring strategic investment banking and capital advisory engagements with institutional firms, including specialized groups, to orchestrate upcoming, larger-scale Regulation D and Regulation A structured offerings.

Subsequent Financial Staging and Strategic Roadmap

Demonstrating ongoing institutional and private investor confidence, subsequent to the quarter close, the Company secured an additional $428,037 in cash commitments under Regulation S and an additional $125,000 under Regulation D. Management is concurrently finalizing another $1,000,000 in "circled" private interest from accredited groups and continues to engage with international high-net-worth groups and institutional syndicates for additional strategic funding tranches aimed at scaling an expanding clinical pipeline target of up to $20,000,000.

Management believes that these secured funds, combined with active financing pipelines, are sufficient to satisfy our administrative and research overhead obligations, support consolidated operations, and advance our corporate strategic roadmap over the next twelve months. This strategic roadmap includes supporting the progression of our PCAOB-level audit process, which formally commenced on May 5, 2026, alongside targeted pre-audit readiness work to ensure efficient final hand-off to the principal auditors. Successful completion and publication of these audited financial statements is designed to satisfy the regulatory transparent reporting requirements necessary for the Company's planned up-listing application to the OTCQB or OTCQX market tiers, to be followed by a Rule 15c2-11 application with FINRA to re-establish a public market quote under our updated corporate identity.

`

NOTE 4– PROPERTY PLANT AND EQUIPMENT

Legacy Assets and Strategic Disposition
Following the foreclosure of LLR on December 23, 2022, and the subsequent divestment of legacy entities (PAA, Gallo, and LC57), the Company shows **no property, plant, and equipment** for the comparative periods ending September 30, 2025, and September 30, 2024.

Terminal Loss (Year Ended September 30, 2025)
For the fiscal year ended September 30, 2025 (recasted), the Company recognized a **Loss on Disposal of Assets (Terminal Loss) of $1,885,648 (USD)**. This loss resulted from the strategic decision to vacate a legacy operating facility that was not **GMP (Good Manufacturing Practice) compliant**. Management determined that the financial burden of remediating that site was not in the shareholders' best interest, choosing instead to exit and preserve capital for a superior infrastructure.

Strategic Acquisition of GMP Facility and Equipment (Effective January 2026) In January 2026, the Company successfully negotiated and entered into a **lease-to-own agreement** for a specialized pharmaceutical manufacturing site. This acquisition includes:

- **Infrastructure:** A 20,477 sq. ft. facility engineered to strict cGMP and ISO 8 clean room standards.
- **Equipment:** The agreement includes all specialized laboratory, manufacturing, and diagnostic equipment currently housed within the facility.
- **Valuation and Cost Basis:** The facility and equipment represent a significant strategic acquisition for the Company. While historical investment in the site's build-out and specialized equipment is estimated at **$30,000,000 CAD (approx. $22,200,000 USD)**, the Company has secured a lease-to-own purchase price of **$10,500,000 CAD (approx. $7,770,000 USD)**.

This **$14.4 million USD discount** to the historical build-out cost allows the Company to scale its drug development and **Point-of-Care Testing (POCT)** operations with a high-value asset base while maintaining a lean capital structure. The facility provides the necessary "hospital-grade" environment for the development of botanical and novel neuroplastogens and the manufacturing of the SpectroChip kit platform.

NOTE 5 – COMMITMENTS AND CONTINGENCIES

Related-Party Loan Agreement
The Company's Canadian subsidiary maintains an active intercompany loan agreement with its founding entity, PurMinds Holdings Inc., to support operational liquidity. The original principal balance bears interest at a fixed rate of 15% per annum. Under the terms of this arrangement, the Company makes structured payments of approximately $30,000 CAD per month toward the facility. As of March 31, 2026, the Company remains fully compliant with the payment terms.

Strategic R&D and Licensing Commitments
The Company has entered into material strategic agreements to advance its neuromedicine and diagnostic platforms:
1. SpectroChip Global Inc. Alliance: The Company has executed a strategic alliance agreement with SpectroChip Global Inc. for the exclusive rights to a proprietary photonic chip diagnostic platform. Under the terms of this agreement, the Company incurred a $250,000 licensing fee during the six months ended March 31, 2026, which has been fully expensed within Research and Development (R&D) costs.
2. Clinical Research Institution Agreement: The Company maintains a collaborative research commitment with a premier U.S. clinical research institution to develop its clinical neuromedicine programs. For the six months ended March 31, 2026, the Company allocated and expensed $100,400 under this collaborative program framework.

Legal and Regulatory Contingencies
As of March 31, 2026, the Company successfully finalized a regulatory government audit regarding its historical Scientific Research and Experimental Development (SR&ED) tax credits within its Canadian subsidiary architecture. This final administrative conclusion resulted in a non-recurring adjustment of $106,891, representing a 50% reduction against the historical legacy estimated asset baseline. The remaining balance has been successfully secured as a non-dilutive capital recovery. There are no other pending legal proceedings, unrecognized tax positions, or unasserted claims that management expects to have a material adverse effect on the Company's financial position.

NOTE 6 -NOTES PAYABLE AND DEBT

Legacy Shell Debt Extinguishment (Pre-RTO)
In preparation for the corporate restructuring and the subsequent Reverse Takeover of 10763942 Canada, Inc. (aka PurMinds NeuroPharma), the Company finalized the extinguishment of all legacy debt obligations associated with the predecessor shell. These liabilities were not assumed as part of the RTO and have been eliminated from the Company's books.

`

- **Alpha Capital Anstalt:** A note originally issued in September 2020 ($26,600 principal plus 8% accrued interest) was formally forgiven and recognized as a gain on extinguishment of debt. As of June 30, 2023, the balance for both principal and interest was **$0**.
- **Tarpon Bay Partners LLC (assigned to Frondeur Partners LLC):** A note originally issued in September 2020 ($13,400 principal plus 8% accrued interest) was formally forgiven and recognized as a gain on extinguishment of debt. As of June 30, 2023, the balance for both principal and interest was **$0**.

Summary of Outstanding Debt
The following table summarizes the Company's debt obligations as of March 31, 2026. These balances reflect the "recasted" financial position following the Reverse Takeover (RTO)

Lender / Category	Type	Interest Rate	Maturity Date	As at Mar 31, 2026
Notes payable, 3rd party (Current)				
TD Bank - CERB Loan	Interest bearing	5%	31-Dec-26	$72,720
Legacy Convertible Notes	Interest bearing	8%	TBD	$966,537
			sub-total	**$1,039,257**
Notes payable, related party (Long-term)				
SAFE Liability	Original 12 - PurMinds Holdings Investors	$0.0334	Conv Rate	$3,705,671
		$0.0668	Conv Rate	$2,263,328
			sub-total	$5,968,999
PurMinds Holdings Inc.	Non-Arm's Length	15%	TBD	$1,145,834
Total Notes Payable			**TOTAL**	**$8,154,090**

NOTE 7 – CONVERTIBLE NOTES PAYABLE

Convertible notes payable balances were as follows:

Lender / Category	Type	Interest Rate	As at Mar 31, 2026	As at Sep 30, 2025
PFSF				
Trillium Partes LP - Principal	$74,898-accrued int.	10% + 24%	$0	$140,000
Alpha Capital - Principal	$110,405–accrued int.	10% + 18%	$0	$160,000
		sub-total	**$0**	**$300,000**
10763942 Canada, Inc.				
Tom Brothers Financial Inc.	Paid out Jan 30, 2026	15%	$0	$85,434
Danaxia Lin	TBD	TBD	$111,111	$109,483
Lin Lu	TBD	TBD	$37,037	$36,494
Ying Dan	TBD	TBD	$161,914	$159,543
Total Notes Payable		**sub-total**	**$310,062**	**$390,954**
		TOTAL	**$310,062**	**$690,954**

Recapitalization and Gain on Extinguishment

In conjunction with the November 3, 2025 RTO and recapitalization, all convertible notes except for the $300,000 legacy principal shown above were forgiven. The Company recognized a total **gain on debt extinguishment of $8,089,600**. This gain includes the forgiveness of principal and interest for notes discussed in Note 6 , the cancellation of warrants and dilutive legacy equity instruments tracked in Note 3 and the elimination of related historical derivative liabilities.

Irrevocable Transfer Agent Instructions (ITAI) and Conversions

`

As of September 15, 2023, ITAIs were issued to resolve legacy shell debt through the issuance of common shares. These instructions were finalized as follows:

- **Alpha Capital:** 13,520,252 common shares relating to the $160,000 note plus $110,405 in accrued interest.
- **Trillium and Oscaleta Partners LLC:** 13,108,339 common shares relating to the $140,000 note plus $122,167 in accrued interest.

Final Debt Resolution (Subsequent Events) The Company has successfully cleared these liabilities to ensure a clean balance sheet for **PurMinds Enterprises, Inc.**:

1. **Trillium Conversion:** Converted 5,863,390 shares on November 19, 2025.
2. **Legacy Cleanup:** All remaining balances for Alpha and Trillium were fully converted into common stock on **January 29, 2026**.
3. **Tom Brothers Payout:** The note held by Tom Brothers Financial Inc. was **paid out in full on January 30, 2026**.
4. **Remaining Subsidiary Debt:** The remaining balances for Danaxia Lin, Lin Lu, and Ying Dan are being addressed via the post-RTO recapitalization plan.

Convertible Notes with Fixed Percentage Conversion Terms Treated as Stock Settled Debt

All forgiven.

NOTE 8– TEMPORARY EQUITY

The preferred series B shares have been determined, by the Company, to be conditionally redeemable upon the occurrence of certain events that are not solely within the control of the Company; but upon such occurrence, redeemable at the option of the holders. They are therefore classified as temporary equity. The purpose of this classification is to convey that such a security may not be permanently part of equity and could result in a demand for cash, securities, or other assets of the entity in the future. The shares valued have been classified as temporary equity and presented as such on the consolidated balance sheet and statement of shareholders deficit, as single line items due to the immaterial par value. The temporary equity value is not included in shareholders' deficit.

Series B Preferred Stock

Authorization and Status
The Company authorized 22,000 shares of Series B Convertible Preferred Stock, par value $0.10. These shares were non-voting and featured a variable conversion mechanism. As of March 31, 2026, there were **1,000 shares** of Series B Preferred Stock issued and outstanding.

Subsequent Cancellation (Board Resolution #2026-001)
Pursuant to **Board Resolution #2026-001**, dated **January 30, 2026**, the Company's Board of Directors authorized the formal cancellation and retirement of all remaining 1,000 shares of Series B Preferred Stock.

- **Consideration:** These shares were surrendered and cancelled as part of the Company's final recapitalization and RTO-related cleanup.
- **Dividends:** No dividends were declared, accrued, or paid on these shares prior to their retirement.
- **Current Standing:** Following this resolution, as of the date of this report, there are **zero (0)** shares of Series B Preferred Stock outstanding.
-

NOTE 9 – STOCKHOLDERS' DEFICIT

Preferred Stock

The Company is currently authorized to issue 50,000,000 shares of preferred stock.

Series A Preferred Stock

Authorization and Status
The Company is authorized to issue 3,000,000 shares of Series A Convertible Preferred Stock, par value $0.001. Each share of Series A is convertible into ten (10) shares of common stock and carries ten (10) votes per share.

Issuance and Cancellation History

- **Settlement and Adjustments:** In April 2025, the Company issued 233,000 shares in settlement of shares previously cancelled. Additionally, 66,000 shares previously issued for services related to the Dreamaderm transaction were cancelled.
- **Period End Balances:** As of September 30, 2025, and March 31, 2026, there were **2,226,000** shares of Series A Preferred Stock issued and outstanding (representing a potential conversion into **22,260,000** common shares).

`

Subsequent Redemption and Retirement (Board Resolution #2026-001)
Pursuant to **Board Resolution #2026-001**, dated **January 30, 2026**, the Company's Board of Directors authorized the formal redemption and retirement of all **2,226,000** outstanding shares of Series A Preferred Stock.

- **Terms:** The shares were redeemed as part of the final recapitalization and closing of the PurMinds Reverse Takeover.
- **Current Standing:** Following this resolution, all Series A voting rights and conversion privileges have been extinguished. As of the date of this report, there are **zero (0)** shares of Series A Preferred Stock outstanding.

Series C Preferred Stock

Authorization and Issuance
The Company is authorized to issue 101 shares of Series C Preferred Stock, par value $0.001 per share. On **October 14, 2025**, pursuant to a resolution by the Board of Directors, the Company authorized the issuance/transfer of **101 shares** of Series C Preferred Stock to **Janet Qi**, the Company's Chief Executive Officer, in connection with the Change of Control and Reverse Takeover (RTO) of PurMinds Holdings Inc.

Super-Voting Rights and Control
The Series C Preferred Stock is non-convertible. Per the Certificate of Designation, the shares carry super-voting rights according to the following formula:

- *Total common stock eligible votes divided by 0.049.*

These rights were established to ensure stable management control during the Company's recapitalization and transition to an operating entity.

Term and Expiration
The shares feature a mandatory expiration "sunset" provision. The Series C shares shall be retired upon the earlier of:

1. **36 months** from the date of the original authorization (April 27, 2021); or
2. The Company's receipt of an investment totaling at least **$10,000,000**.

Current Status
As of March 31, 2026, there are **101 shares** of Series C Preferred Stock issued and outstanding, all of which are held by Janet Qi.

Series D Preferred Stock

Authorization and Terms
On November 12, 2021, the Company authorized 1,600 shares of Series D Preferred Stock, par value $0.001. The Series D shares were non-voting, did not carry dividend rights, and featured a conversion right into 0.01% of the total common stock outstanding at the time of conversion.

Cancellation and Current Status
Effective April 1, 2023, the shareholders agreed to surrender all outstanding Series D shares for cancellation as part of the Company's debt and equity restructuring.

As of **September 30, 2025**, and **March 31, 2026**, there were **zero (0) shares** of Series D Preferred Stock issued or outstanding. The Company does not intend to issue any further shares under this designation.

Common Stock and Warrants

The Company is authorized to issue **1,950,000,000** shares of common stock, par value **$0.001** per share.

Issued and Outstanding Shares

- As of **March 31, 2026**, there were **773,446,598** shares of common stock issued and outstanding.
- As of **September 30, 2025**, there were **47,204,669** shares of common stock issued and outstanding.

The increase in shares outstanding during the period ended September 30, 2025, primarily reflects shares issued in connection with the Reverse Takeover (RTO) and the settlement of legacy obligations.

Private Placement (Regulation S) During the quarter ended March 31, 2026, the Company completed a private placement of its common stock with non-U.S. investors under the provisions of Regulation S of the Securities Act of 1933, as amended. The Company received aggregate cash proceeds of $2,101,781 in connection with this offering. As of March 31, 2026, the underlying shares of common stock associated with this transaction had been formally issued by the Company's Transfer Agent, and the proceeds have been fully recorded within Common Stock and Additional Paid-in Capital on the Consolidated Balance Sheet.

`

Stock Subscriptions Received (Regulation D) During the quarter ended March 31, 2026, the Company received cash proceeds totaling $40,000 from investors in connection with a private placement of common stock under Regulation D of the Securities Act of 1933, as amended. As of March 31, 2026, the underlying shares of common stock had not yet been formally issued by the Company's Transfer Agent. Accordingly, the $40,000 has been recorded as Stock Subscriptions Received within the Stockholders' Equity section of the Consolidated Balance Sheet.

Debt Conversion During the three months ended March 31, 2026, the Company issued common shares upon the conversion of **$117,268** in principal and interest of convertible debentures. This non-cash transaction resulted in a reduction of liabilities and a corresponding increase to Common Stock and Additional Paid-in Capital.

Warrants Issued

All warrants issued were cancelled effective April 1, 2023, in conjunction with a recapitalization.

Due to the aforementioned foreclosure the Company has no non-cancellable lease obligations.

NOTE 10 – REVERSE TAKEOVER, RECAPITALIZATION, AND SUBSEQUENT EVENTS

A. Reverse Takeover (RTO) and Corporate Restructuring

On November 3, 2025, the Company completed a Reverse Takeover ("RTO") with PurMinds Holdings Inc. (including its 100% owned subsidiary, 10763942 Canada Inc., dba PurMinds NeuroPharma), a clinical-stage neuromedicine company. This transaction established a new control group and management team.

For accounting purposes, this transaction is treated as a reverse acquisition and recapitalization of the Canadian entity, with PurMinds Holdings Inc. identified as the accounting acquirer and the Company as the accounting acquiree. Consequently, the historical financial statements prior to the RTO date will be those of the accounting acquirer.

In connection with the RTO and the finalization of conversions and redemptions completed on January 30, 2026, the corporate restructuring included the following:

- **Equity Issuance:** The Company issued an aggregate of 627,275,009 shares of common stock (consisting of tranches of 581,036,003 and 46,239,006 shares) to the former shareholders of the Canadian entity. Following these issuances, the former shareholders of PurMinds held approximately 90% of the Company's total issued and outstanding common stock.
- **Series C Issuance:** The Company issued 101 shares of Series C Convertible Preferred Stock to Janet Qi, CEO of PurMinds, establishing voting control.
- **Identity Change:** A corporate name change to PurMinds Enterprises, Inc. has been approved by the State of Nevada. The Company has submitted applications to FINRA, which is currently processing the final corporate name and ticker symbol changes.

B. Disposition of Legacy Assets and Debt Settlements

During the period ended March 31, 2026, the Company finalized the cleanup of its legacy "shell" obligations and terminated prior asset agreements to align entirely with its new business focus:

- **Dreamaderm/Regents Termination:** The prior acquisition of assets from Dreamaderm, Inc. and the licensing agreement with the Regents of the University of California were formally terminated. On January 31, 2026, the 1,500,000 common shares previously issued for these assets were returned to the Company and cancelled.
- **Debt & Contract Settlement:** The Company approved the transfer of legacy assets (A.L.Z. DEFENSE, SuppleMEM T, and ScalerAide for Pets) to Harrysen Mittler. In exchange, Mr. Mittler agreed to the full cancellation of his executive contract (dated May 23, 2023) and the complete cancellation of a corporate promissory note owed to him in the amount of $160,000.
- **Preferred Share Redemptions:** All prior Series A Preferred shares were surrendered and redeemed, and 2,000 shares of Series B Preferred shares were cancelled, concluding all material prior management equity obligations.

C. Capital Raising Activities During the Period

During the quarter ended March 31, 2026, the Company expanded its private capital placement initiatives:

`

- March 2026 Placements & Strategic Allocation: As described in the Stockholders' Equity statements, the Company received an additional $2,101,781 in completed Regulation S closures and $40,000 in Regulation D stock subscriptions received. Total private funding raised or committed since the RTO exceeds $2.25 million, with future tranches targeted up to $20 million.
- During the period, the Company deployed $350,400 of its available capital directly into its primary clinical and diagnostic development paths, consisting of a $250,000 licensing fee paid to SpectroChip Global Inc. and $100,400 to a premier U.S. clinical research institution for collaborative neuromedicine research programs.

D. Subsequent Events

The Company has evaluated subsequent events through the date these financial statements were available to be issued, and identified the following material disclosures:

- **Subsequent Capital Receipts (Through May 20, 2026):** Subsequent to the quarter ended March 31, 2026, the Company received additional cash commitments and proceeds totaling **$428,037** under Regulation S and **$125,000** under Regulation D. The underlying common shares for these tranches are currently pending formal issuance by the Company's Transfer Agent.
- **PCAOB Audit Engagement:** On May 5, 2026, the Company formally commenced its PCAOB-level audit process. To optimize efficiency and accelerate the completion timeline, the Company engaged an independent professional accounting firm to perform comprehensive pre-audit preparation and readiness work. This preparation ensures the financial records are fully optimized before final hand-off to the principal PCAOB audit team. This audit is being conducted to satisfy regulatory requirements for the Company’s planned up-listing application to the OTCQB or OTCQX market tiers.
- **Market Maker Engagement & Form 211:** Upon successful completion and publication of the PCAOB-audited financial statements, the Company intends to engage a Market Maker to file a Rule 15c2-11 application with FINRA to re-establish a public market quote under its new corporate identity.